WT

WisdomTree Expands Thematic Range with a Blockchain UCITS ETF

Retrieved on: 
水曜日, 9月 14, 2022
European Economic Area, Central bank, Issuer, Communication, ESG, Advertising, Sale, EEA, Investment Company Act of 1940, Investment fund, Policy, Central Bank of Ireland, WT, ETP, United Kingdom, Prospectus, Index, WisdomTree Investments, Undertakings for Collective Investment in Transferable Securities Directive 2009, Insurance, Security (finance), Share (finance)

WisdomTree Ireland Limited and WisdomTree UK Limited are each referred to as WisdomTree (as applicable).

Key Points: 
  • WisdomTree Ireland Limited and WisdomTree UK Limited are each referred to as WisdomTree (as applicable).
  • Back tested data does not represent actual performance and should not be interpreted as an indication of actual or future performance.
  • Although WisdomTree endeavours to ensure the accuracy of the content in this document, WisdomTree does not warrant or guarantee its accuracy or correctness.
  • Where WisdomTree has expressed its own opinions related to product or market activity, these views may change.

Parse Biosciences Releases Whole Transcriptome Version 2 Chemistry with Marked Performance Enhancements

Retrieved on: 
火曜日, 8月 30, 2022
Other Health, Research, General Health, Oncology, Technology, Science, Biotechnology, Neurology, Stem Cells, Other Technology, Other Science, Health, Transcript, CEO, Technology, RNA-Seq, Kidney, WT, Chemistry, Cell, Transcriptome, Immune system, List of life sciences, CTO, Health, Bias, Electric battery, Vaccine

Parse Biosciences , a leading provider of accessible and scalable single cell sequencing solutions, announced today a significant performance update of its chemistry for the Evercode Whole Transcriptome products.

Key Points: 
  • Parse Biosciences , a leading provider of accessible and scalable single cell sequencing solutions, announced today a significant performance update of its chemistry for the Evercode Whole Transcriptome products.
  • Our Evercode products are empowering labs across the world with accessible and scalable single cell sequencing, said Alex Rosenberg, CEO and cofounder of Parse Biosciences.
  • With the release of our new Evercode Whole Transcriptome v2 chemistry, we continue to deliver on that promise - providing unmatched performance to single-cell researchers.
  • For additional information about Parse Biosciences newest version, visit https://www.parsebiosciences.com/products/evercode-whole-transcriptome
    Parse Biosciences is a Seattle-based company with the mission of accelerating progress in human health and scientific research.

WT Group Announces Joint Venture With Greenwich Energy Solutions

Retrieved on: 
水曜日, 8月 24, 2022
COO, CEO, Technology, WTS Group, Surveying, Engineering, Carbon, Solution, Electricity, WT, Forest Law Enforcement and Governance Program, Education, GLOBE, Construction management, GES, Compliance, OSP, Efficiency, Climate change, Renewable energy, Audit, Telecommunication

WT Group and Greenwich Energy Solutions are fully-versed in government programs that will benefit clients financially and can provide clients with education, energy efficiency audits, retrofit project management, energy supply procurement and brokerage, strategic consulting for long-term management and technology assessments.

Key Points: 
  • WT Group and Greenwich Energy Solutions are fully-versed in government programs that will benefit clients financially and can provide clients with education, energy efficiency audits, retrofit project management, energy supply procurement and brokerage, strategic consulting for long-term management and technology assessments.
  • Stephen Hughes, President & COO of Greenwich Energy Solutions, added, "We're extremely excited about this venture.
  • Troy Triphahn, President & CEO of WT Group, notes, "WT Group (WT) is thrilled to announce this joint venture with Greenwich Energy Solutions (GES).
  • Headquartered in Brooklyn, New York, Greenwich Energy Solutions is one of the premier providers of independent energy solutions in the Northeast.

Elite Climber Alex Honnold Leads First Ascent of One of the Tallest Unclimbed Rock Faces on Earth

Retrieved on: 
木曜日, 8月 18, 2022
Film & Motion Pictures, Sports, Extreme Sports, Entertainment, TV and Radio, Multimedia, Face, Snow, EDGE, National Geographic, WT, Ice, Empire, ALEX, Weather, Findlay, Groundwater Ambient Monitoring and Assessment Program, Scoresby Sound, Granite, Honnold, Greenlandic

The cliff, composed of 3-million-year-old granite and gneiss, rises 3,750 feet out of a remote peninsula jutting into a fjord on Greenlands eastern coast.

Key Points: 
  • The cliff, composed of 3-million-year-old granite and gneiss, rises 3,750 feet out of a remote peninsula jutting into a fjord on Greenlands eastern coast.
  • Honnold and Findlay were able to free-climb the entire route of the 3-million-year-old rock.
  • WHEN: After a 5-day climb battling icy weather conditions, Honnold and Findlay successfully summited the granite-gneiss rock face on Tuesday, Aug. 16.
  • It ranks among the tallest big walls ever climbed and heretofore stood as perhaps one of the biggest unclimbed rock faces in the world.

HUB INTERNATIONAL BOLSTERS RETIREMENT PLAN CONSULTING SERVICES WITH THE ADDITION OF BILL MCCLAIN IN ILLINOIS

Retrieved on: 
火曜日, 8月 9, 2022
RIA, Industry, Hub International, Wealth, LLC, Risk management, Retirement, Broker-dealer, RPW, WT, Insurance, Solution, Organization, Financial services, Financial adviser, Hub

This move continues to expand Hub RPW with the addition of talent and resources to develop more comprehensive strategies for clients.

Key Points: 
  • This move continues to expand Hub RPW with the addition of talent and resources to develop more comprehensive strategies for clients.
  • Hub Retirement and Private Wealth ("RPW") offers institutional and retirement services to for-profit and not-for-profit organizations and customized private wealth management services to individuals and families.
  • Global Retirement Partners, LLC, Millennium Advisory Services, Inc, TCG Advisory Services, LLC, Hub Investment Advisors, LLC, Hub International Investment Advisory Services, Inc., and Sheridan Road Advisors, LLC are wholly owned subsidiaries of Hub.
  • Headquartered in Chicago, Illinois, Hub International Limited is a leading full-service global insurance broker and financial services firm providing risk management, insurance, employee benefits, retirement and wealth management products and services.

Gain Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Business Update

Retrieved on: 
月曜日, 8月 8, 2022
MDS, XXVII, Survival, Drug discovery, GLOBE, Technology, Neuron, IP, Clinical trial, Brain, GD, Lysosome, Krabbe disease, Investment, GBA1, PD, IND, Research, Patient, Therapy, Company, Toxicology, Program, Glycogen storage disease, Neurodegeneration, STAR, GAAP, Gaucher's disease, Alpha-synuclein, Lead, WT, Protein, Nasdaq, Pharmaceutical industry, Online gambling, Medical imaging, Medical device, Cryptocurrency, Lease

We move into the second half of 2022 having made tangible progress across our pipeline, said Eric Richman, Chief Executive Officer of Gain Therapeutics.

Key Points: 
  • We move into the second half of 2022 having made tangible progress across our pipeline, said Eric Richman, Chief Executive Officer of Gain Therapeutics.
  • Net loss was $5.08 million compared to $3.56 million in the second quarter 2021.
  • GAAP basic and diluted net loss per share was $0.43, compared to basic and diluted net loss per share of $0.30 in the second quarter 2021.
  • Cash, cash equivalents and marketable securities were $29.1 million as of June 30, 2022 compared to $36.8 million at December 31, 2021.

Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates

Retrieved on: 
金曜日, 6月 17, 2022
Histocompatibility, Cancer, NK, International Society for Stem Cell Research, MHC, Eye, Therapy, Drug development, COVID-19, SANA, Escape Room, Latent autoimmune diabetes in adults, Tissue, NHP, Gene, Social disruption, Syngenic, CD19, Survival, CAR, Company, Immunosuppression, RPE, HIP, Research, Retinal pigment epithelium, Sana, Disease, Biotechnology, Lymphatic system, Immune system, Potency (pharmacology), International Society, NASDAQ, IND, NOD, Degenerative disease, Patient, Terminology, ISSCR, CD47, Cell, Macrophage, IPSC, Annual general meeting, Risk, GLOBE, WT, Mouse, Vaccine, Pharmaceutical industry

SEATTLE, June 17, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, presented data showing survival of transplanted allogeneic, hypoimmune cells of several different types in a variety of locations in non-human primates (NHPs). The transplanted cells were induced pluripotent stem cell (iPSC)-derived cardiomyocytes, retinal pigment epithelium (RPE) cells, and islet cells, which were engineered to include Sana’s hypoimmune gene modifications that enable immune evasion. Data were presented by Sonja Schrepfer, M.D., Ph.D., Head of Hypoimmune Platform at Sana, during sessions at the International Society for Stem Cell Research (ISSCR) 2022 Annual Meeting taking place from Wednesday, June 15 through Sunday, June 19 in San Francisco.

Key Points: 
  • Transplanting cells or tissues from a donor to a different recipient currently requires intense immunosuppression to prevent rejection of the transplant.
  • Sanas HIP platform goal is to eliminate the need for immunosuppression by cloaking cells from immune recognition.
  • These changes alone make cells susceptible to innate immune cell killing, in particular by natural killer (NK) cells.
  • In this study, allogeneic primary pancreatic islet cells were HIP edited and transplanted intramuscularly into a healthy NHP without immunosuppression (n=1) as proof-of-concept.

Trade and Earn WT Token Effortlessly on XT.COM

Retrieved on: 
木曜日, 6月 16, 2022
Crypto, Ethereum, Time, Blockchain, Global, Ecosystem, WT, WCEX, Income, Cryptocurrency, Binance, USDT

Moreover, WT functions as a peer-to-peer native token with value-added privileges within the Wohlstand crypto business ecosystem.

Key Points: 
  • Moreover, WT functions as a peer-to-peer native token with value-added privileges within the Wohlstand crypto business ecosystem.
  • WT token can be purchased, traded, staked, and used to perform crypto-related transactions.
  • Anisor, the Global CMO of XT.com stated, "We are proud to add trading support for WT token on XT.COM.
  • We also encourage our global users to engage in active WT token trading and withdrawal on our platform."

Critically Acclaimed Documentary, Mr. SOUL! Receives the 2022 Peabody Award

Retrieved on: 
火曜日, 6月 7, 2022
NBCUniversal, Congress, Executive producer, Gang, Stephen Curry, WT, Black Joy, Academy Award for Outstanding Achievement in Popular Film, Peabody Award, American Film Festival, Politics, Show Me Your Soul, Humble (production studio), Poverty, Critic, Music, The Last Poets, Television, Social justice, Lisa Ellis (executive producer), Sport, Radio, Poetry, African Americans, The New York Times, Woodstock Film Festival, NBC, Violence, Universal, Mavis Staples, Collection, Academy Awards, Kool, Jacob Burns Film Center, HBO Max, NAACP Image Awards, PBS, Arsenio Hall, Peabody, Cinema Eye Honors, Burns, Black Arts Movement, Mr. Soul, Melissa, 93rd Academy Awards, Life, AFI, Film, Audience award, Woman, Pan African Film Festival, NEW, Twitter, Board, Instagram, List of common film awards categories, Nightclub, Public relations, Best, Arsenio

NEW YORK, June 7, 2022 /PRNewswire/ -- Produced, written and directed by Melissa Haizlip, the celebrated documentary, "Mr. SOUL!" is the proud recipient of the prestigious 2022 Peabody Award. The winning announcement was made by Academy Award-winning actor Morgan Freeman. The award is being presented for the PBS broadcast of "Mr. SOUL!" which premiered on Independent Lens during Black History Month 2021. Recognized by The New York Times as a top Streaming Pick, "Mr. SOUL!" is the winner of the Best First Documentary Feature at the 2020 Critics Choice Documentary Awards, and Outstanding Writing in a Documentary (Television or Motion Picture) at the 52nd NAACP Image Awards. "Mr. SOUL!" was also shortlisted at the 93rd Academy Awards in the category of Best Original Song, for "Show Me Your Soul" by Grammy Award-winning composer Robert Glasper and Grammy Award-winning singer Lalah Hathaway.

Key Points: 
  • centering Black Joy
    NEW YORK, June 7, 2022 /PRNewswire/ -- Produced, written and directed by Melissa Haizlip, the celebrated documentary, "Mr.
  • is the proud recipient of the prestigious 2022 Peabody Award.
  • SOUL!"
  • SOUL!"

Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update

Retrieved on: 
月曜日, 5月 16, 2022
Clinical trial, Autophagosome, Research, Survival, Nasdaq, GD, Gaucher's disease, Neurodegeneration, Patient, GBA1, Alpha-synuclein, Information technology, Trial of the century, Therapy, Macrophage, XXVII, AD, Hope, Neuron, Brain, CNS, Lysosome, Conference, GBA, Lead, Parkinson, Program, WORLD, Liver support system, Allosteric regulation, PD, GAAP, Drug discovery, Potency (pharmacology), GLOBE, Medical device, Pharmaceutical industry, Aquaculture, Airline, WT, Gaucher

BETHESDA, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced its financial results for the first quarter ended March 31, 2022, and highlighted recent corporate accomplishments.

Key Points: 
  • This has been a productive quarter for Gain, as we continued to demonstrate the broad reaching potential of our SEE-Tx platform, said Eric Richman, Chief Executive Officer of Gain Therapeutics.
  • Our strategy of exploring previously unidentified allosteric binding sites and targeting them for therapeutic benefit has proved promising.
  • In March, Gain presented, Targeting Glucocerebrosidase with Structurally Targeted Allosteric Regulators Corrects Abnormal Phenotypes in Models of Parkinsons Disease.
  • Cash and cash equivalents were $34.34 million as of March 31, 2022 compared to $36.88 million at December 31, 2021.